Literature DB >> 1466765

Enkephalin is a competitive antagonist of cholecystokinin in the gastrointestinal tract, as predicted from prior conformational analysis.

R B Murphy1, M R Pincus, M Beinfeld, D C Dykes, J M Chen, L H Schneider, J Gibbs, G P Smith.   

Abstract

Prior calculations based on ECEPP (Empirical Conformational Energies for Peptides Program) of the low energy minima for cholecystokinin (CCK) and Met-enkephalin have demonstrated that significant structural features of these two peptides are identical. This result suggested the possibility that Met-enkephalin, as well as other enkephalin analogues of similar structure, could associate with receptors for CCK. To test this theoretical result, we examined the ability of Met-enkephalin and its analogues to bind to peripheral CCK receptors in the rat gastrointestinal tract; in particular, we measured the ability of the opiate peptide to inhibit the effects of CCK in a physiological assay system which we have previously characterized: CCK-induced contraction of the isolated rat pyloric sphincter. We find that Met-enkephalin is an antagonist of the CCK-8-induced contraction, with a IC50 of 110 nM. Furthermore, antibodies against CCK were found to cross-react with Met-enkephalin and its analogues in a manner which suggests a distinct structure-activity relationship. These experimental results strongly support the theoretical results of conformational analysis showing structural similarity between enkephalin and CCK. They further suggest that enkephalins could modulate the response of CCK systems under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1466765     DOI: 10.1007/bf01024973

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  21 in total

1.  Extrinsic and intrinsic neural control of pyloric sphincter pressure in the dog.

Authors:  H D Allescher; E E Daniel; J Dent; J E Fox; F Kostolanska
Journal:  J Physiol       Date:  1988-07       Impact factor: 5.182

2.  An approach to the multiple-minima problem in protein folding by relaxing dimensionality. Tests on enkephalin.

Authors:  E O Purisima; H A Scheraga
Journal:  J Mol Biol       Date:  1987-08-05       Impact factor: 5.469

3.  Prediction of the native conformation of a polypeptide by a statistical-mechanical procedure. I. Backbone structure of enkephalin.

Authors:  G H Paine; H A Scheraga
Journal:  Biopolymers       Date:  1985-08       Impact factor: 2.505

4.  Characterization of cholecystokinin receptors on the sphincter of Oddi.

Authors:  K L Cox; T von Schrenck; T H Moran; J D Gardner; R T Jensen
Journal:  Am J Physiol       Date:  1990-11

5.  On the biologically active structures of cholecystokinin, little gastrin, and enkephalin in the gastrointestinal system.

Authors:  M R Pincus; R P Carty; J Chen; J Lubowsky; M Avitable; D Shah; H A Scheraga; R B Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

6.  Two brain cholecystokinin receptors: implications for behavioral actions.

Authors:  T H Moran; P H Robinson; M S Goldrich; P R McHugh
Journal:  Brain Res       Date:  1986-01-01       Impact factor: 3.252

7.  Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.

Authors:  R S Chang; V J Lotti; T B Chen; K A Kunkel
Journal:  Mol Pharmacol       Date:  1986-09       Impact factor: 4.436

8.  Cholecystokinin receptors on gallbladder muscle and pancreatic acinar cells: a comparative study.

Authors:  T von Schrenck; T H Moran; P Heinz-Erian; J D Gardner; R T Jensen
Journal:  Am J Physiol       Date:  1988-10

9.  Enkephalin: conformational analysis by means of empirical energy calculations.

Authors:  Y Isogai; G Némethy; H A Scheraga
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

10.  In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.

Authors:  V J Lotti; R G Pendleton; R J Gould; H M Hanson; R S Chang; B V Clineschmidt
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.